Loading
A phase 2 trial of Ivonescimab, Olaparib in ovarian cancer, run by Akeso, now recruiting.
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer is a phase 2 interventional study registered as NCT06686030 by Akeso, with 150 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10. Interventions recorded: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose. Conditions listed: Platinum-sensitive Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Akeso, Ivonescimab, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Akeso, Ivonescimab.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Olaparib, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/